Vivek Jain: Sure. I’ll answer that one. Our job, our responsibility regardless of our own or what we acquired is to be improving on the quality scores every single day. And so there’s never a day of sort of waiting around. I think the expectation is that you’re improving, you’re improving your situation. And that can mean a lot of different things that can mean assessing every single product and where there’s applicable notifications to customers making some of those notifications like we’ve referenced on the last two call scripts and you’ve seen in the various reports, it can also mean researching all the historical plates to make sure everyone is adequate can close. We’ve done a mountain of work. You’ve seen the investments into the quality remediation that we’ve put in for eight quarters.
You’re never really done. We think we’ve come a long, long way and we hope we get the opportunity to show that too somebody, but it’s not really — you just hit a line and stop it and never ends.
Brett Fishbin: That makes a lot of sense. Thank you for taking the questions,
Operator: Your next question comes from the line of Kristen Stewart from CL King. Your line is open.
Kristen Stewart: Hi. Congrats on a good quarter and thanks for taking the question. I was wondering if you could just focus a little bit on free cash flow in the quarter. It was positive which is a great thing. How are you looking for the rest of the year from a cash flow perspective?
Brian Bonnell: Yes Kristen ,I think we got off to a pretty good start to the year especially given Q1 we do tend to have more outflows in that quarter each year. I think — we feel like our previous guidance around free cash flow is still relevant in that it would be basically the same as last year. but without some of the financing benefit that we got which means $80 million roughly give or take for the full year this year. And so I think we’re still very much on track for that.
Kristen Stewart: Okay. Great. And then I just wanted to turn over to Vascular Access. It sounds like that had a good quarter. How should we be thinking about that business going forward?
Vivek Jain: Hey Kristen, it’s Vivek. I think in our mid-single guidance for the Consumables segment for the year, we assume Vascular Access would be in line with that. It is still far below peak historical levels. We’ve just gotten the house in order a bit over the difficulties we had in the first six quarters or something. So, it feels a lot to us sort of what we went through post Hospira with consumables where it really did take two years to be stable and to show that we could move it upwards. And we think we’re in kind of the first part of that journey right now. There’s a long way to go, but I think we at a minimum believe it would be in line with the overall segment.
Kristen Stewart: Okay. Great. Thanks for taking my questions.
Operator: [Operator Instructions] Your next question comes from the line of Larry Solow from CJS Securities. Your line is now open.
Larry Solow: Great. Thank you. I guess coming back to Jason’s question, on the pump market. And you said, it sounds like decisions are being made, so where do you stand? How do you feel with a lot more jump I guess if you will and share of [indiscernible]. You feel like you have an opportunity – clearly, you’ve gained some share in the last couple of years, but now actually back in the market. I think factor is a new pump. How do you feel your positioning is to continue to — I know it’s a slow moving market, but to continue sort of that positive momentum.
Vivek Jain: It is jump ball season. It is the playoffs. I think our view is, also not to sound less than ambitious here or hedge, it’s also relative to the size of our business right, which is the point we were trying to make on the other scripts the last two years, which is our business is actually — it’s big, but it’s not that big relative to the total available market opportunity. And so, if we can increase our win rate above historical levels, it makes a real meaningful difference on our P&L. And we think we have the right technology. And all participants I suspect have more conversations going on that they’ve had in the last number of years, which is good things will settle out. And we just need to — we know what our peak share of our products were.
We know how low they got and why we had to step in Hospira and we know what the opportunity is in front of us. So, we feel good I would leave it at we feel very good about the technology investments, we’ve made and have been committed to for in a good sense of what we think customer preference could be in this product family. And we’ve obviously, suffered a little bit right, but we undertook getting the full line together right between syringe ambulatory et cetera.
Larry Solow: Okay. I appreciate that color. Just on the gross margin, back to that the cadence sounds like maybe we come back down a little bit in Q2, like that where you have a little more inventory scale back as well, and then maybe a little bit of stabilization in the back half, but regarding — just regarding the cadence, but just kind of situationally where do you think they’ll stand as you exit the year mostly inventory management, should be behind you hopefully mix is starting to improve. But do you think you can sort of as we start next year we’re getting — back a little bit off of the sort of mid-30s number and then we get more consolidation benefits next year and work from that maybe you can give us put a little more guidance if you may.
Brian Bonnell: Yes, Larry I think as it relates to this year. On the last call, we said we would expect to exit this year slightly above the 35% average for the year. Absent something unusual happening in terms of product mix or currency or anything like that, I think we still think that’s probably the most likely scenario. And you’re right, that means that then throughout the year we won’t have the steep trajectory in gross margins that we were expecting, it will be a bit more flattish I suppose. But I think our views on where we exit, really haven’t changed.
